A|B|C|D|E|F|G|H|I|J|K|L|M|N|O|P|Q|R|S|T|U|V|W|X|Y|Z|ALL

  检 索： 期刊名称 ISSN         高级检索

期刊名称：EXPERT OPINION ON THERAPEUTIC PATENTS ISSN： 1354-3776 出版频率： Monthly 出版社： TAYLOR & FRANCIS LTD, 2-4 PARK SQUARE, MILTON PARK, ABINGDON, England, OXON, OX14 4RN   出版社网址： http://informahealthcare.com/ 期刊网址： http://informahealthcare.com/loi/etp 影响因子： 6.681 主题范畴： CHEMISTRY, MEDICINAL;    PHARMACOLOGY & PHARMACY 期刊简介(About the journal)    投稿须知(Instructions to Authors)    编辑部信息(Editorial Board)    About the journal   Expert Opinion on Therapeutic Patents (ISSN 1354-3776) is published monthly and is the leading patent journal for pharmaceutical patent information. Expert Opinion on Therapeutic Patents provides a monthly, peer-reviewed guide to the technological advances and developments in pharmaceutical patents. Authors are encouraged to express their Expert Opinion of the status of the research under review, rather than to simply review the available data. Each issue of the journal contains annotated patent selections and short patent evaluations which highlight inventions and innovative ideas deemed by relevant experts to be of potential importance. The audience consists of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in R&D. Subscribers include most of the major pharmaceutical companies in the USA, Europe and Japan, and many biotechnology companies. Expert Opinion on Therapeutic Patents adopts a systematic approach to coverage, with each issue focusing on one of the major therapeutic areas. The major themes covered are as follows: Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis Anti-infective Biologicals, Immunologicals & Drug Delivery Central & Peripheral Nervous Systems Cardiovascular, Renal, Endocrine & Metabolic Oncologic Citations Expert Opinion on Therapeutic Patents is indexed by: Chemical Abstracts Current Contents?Life Sciences EMBASE/Excerpta Medica Instructions to Authors   The Commissioning Editor, under the advice of the Editorial Board, solicits articles published in Expert Opinion on Therapeutic Patents. However, suggestions for article topics (and potential authors) are welcome, subject to final approval by the Editors and Editorial Board. If you are interested in preparing an article, please contact the Commissioning Editor (lucy@ashley-pub.com) with your proposal and an outline. The following guidelines (PDF files) are provided to assist authors in the preparation of their manuscript. Review Patent Evaluation Editorial Expert Opinion EndNote Style Editorial Board   The Advisory Panel and Section Editorial Board are composed of Senior Scientists involved in drug research and development. The Advisory Panel is responsible for the development of the journal, while the Section Editors are responsible for selecting authors and topics for review to ensure comprehensive coverage of subjects in each therapeutic area. Cardiovascular Chakravarty PK: Merck Sharpe & Dohme, USA Dueholm KL: Novo Nordisk, Denmark Grove R: Miravant Medical Technologies, USA Hill C: Organon Laboratories Ltd, UK Jacobson KA: National Institute of Health, USA ler CE: Pharmazeutisches Institut, Germany Rees D: AstraZeneca, Sweden Spada AP: Aventis, USA Suckling KE: GlaxoSmithKline, UK Trybulski E: Wyeth-Ayerst, USA Wester R: Pfizer, USA Pulmonary-Allergy Dominguez C: Amgen, USA Ghosh S: MitoKor, USA Kaminski JJ: Schering-Plough, USA Landry Y: Univ. Louis Pasteur, France Lipani J: Abgenix, Inc., USA Murthy S: MCP Hanemann Univ. of the Health Sciences, USA Norman P: Norman Consulting, UK Sircar JC: Avanir Pharm., USA Summers JB: Abbott, USA Suto M: DuPont Pharmaceuticals, USA Talley JJ: Pharmacia Corp., USA Trivedi B: Pfizer Global R&D, USA Walker E: formerly AstraZeneca, UK Whittaker M: British Biotech, UK Senior Advisory Panel Evans C: Chiroscience, UK Fitzgerald JD: Materia Medica, UK Krogsgaard-Larsen P: Danish School of Pharmacy, Denmark Mullen A: Bayer AG, Germany Poste G: Health Tech. Networks, USA Ross BC: GlaxoSmithKline, UK Steele PR: IP Consultant, UK Stevens RW: Pfizer Global R&D, Japan Terrett N: Pfizer Global R&D, UK Timmermanns P: DuPont, USA de Clercq E: Rega Institut, Belgium Anti-infectives Cooper RDG: Cooper Consulting, USA Croft S: Univ. of London, UK Hector RF: UCSF Prevention Sciences Group, USA Hunter PA: Freelance Consultant, UK Kirst H: Eli Lilly, USA Lee VJ: Microcide, USA Myles D: Kosan Biosciences, USA Ridley R: WHO, Switzerland Supuran C: Univ. di Firenze, Italy Tarby C: DuPont, USA Central & Peripheral Nervous Systemsm Abou-Gharbia M: Wyeth-Ayerst Research, USA Baudy RB: Wyeth-Ayerst, USA Bousquet P: Univ. de Rouen, France Christos T: Sphinx Pharm., USA Cliffe I: Cerebrus, UK Cook J: Univ. of Wisconsin-Milwaukee, USA Franco R: Wyeth-Ayerst, USA Halazy S: Serono Pharm. Res. Inst., Switzerland Hill C: Organon Laboratories Ltd, UK Hoban C: Cambridge Science Consultants, USA Howard H: Pfizer Global R&D, USA Jacobson KA: National Institute of Health, USA Johnson G: Bristol-Myers Squibb, USA Larner A: Walton Centre for Neurology and Neurosurgery, UK McElroy AB: Pfizer Global R&D, UK Nagase H: Univ. of Kansas, USA Smith PW: GlaxoSmithKline, UK Spence RP: Pharmacia Corp., USA Williams M: Abbott, USA Oncologic Baldwin RW: Queen's Medical Centre, UK Beeley NRA: Arena, USA Christos T: Eli Lilly, USA Connell RD: Pfizer Global R&D, USA Connors T: Univ. of London, UK Dale I: AstraZeneca, UK Dalgleish A: St George's Hospital Medical School, UK Davis P: Celltech Therapeutics, UK Desai M: Chiron, USA Ecker G: Univ. of Vienna, Austria Fields G: Florida Atlantic Univ., USA Garrett M: CRC Centre for Cancer Therapeutics, UK Hughes L: AstraZeneca, UK Laight DW: Univ. of Portsmouth, UK Martini L: Univ. di Milano, Italy Myles D: Kosan Biosciences, USA Nuss J: Exelixis, Inc., USA Remuzzi G: Istituto di Ricerche Farmacologiche 'Mario Negri', Italy Skibo E: Arizona State Univ., USA Supuran CT: Univ. di Firenze, Italy